Health Leadership and Quality of Life. 2025; 4:610
doi: 10.56294/hl2025610

ORIGINAL

Agoraphobia and Panic Disorder: Understanding the Symptoms, Diagnosis, and Treatment Options

Agorafobia y trastorno de pánico: Comprensión de los síntomas, diagnóstico y opciones de tratamiento

Devraj Singh Chouhan[1], Saumya Das[2], Prateek Garg[3], Nagireddy Mounika[4], Swamyvel Sethuraman[5], Nittin Sharma[6]

[1]Parul University, Faculty of Nursing. Vadodara, India.
[2]Noida Institute of Engineering and Technology Pharmacy Institute, Greater Noida, India.
[3]Chitkara Centre for Research and Development, Chitkara University, Chandigarh, India.
[4]Anurag University, Centre for Multidisciplinary Research, Hyderabad, India.
[5]Hamad Mental Health Services, Doha, Qatar.
[6]Centre of Research Impact and Outcome Chitkara University, Rajpura, India.

Cite as: Singh Chouhan D, Das S, Garg P, Mounika N, Sethuraman S, Sharma N. Agoraphobia and Panic Disorder: Understanding the Symptoms, Diagnosis, and Treatment Options. Health Leadership and Quality of Life. 2025; 4:610. https://doi.org/10.56294/hl2025610

Submitted: 03-06-2024 **Revised:** 28-10-2024 **Accepted:** 24-05-2025 **Published:** 25-05-2025

Editor: PhD. Prof. Neela Satheesh

Corresponding Author: Devraj Singh Chouhan

ABSTRACT

Agoraphobia with panic disorder (PD) is a phobia-anxiety condition that makes sufferers avoid situations or locations where it could feel embarrassed or be unable to leave or get help in case of a PD. Agoraphobia has been associated with recurrent PD syndrome over the last 50 years, and in many instances, it is regarded to represent the normal progression or complication of PD. Even though agoraphobia with PD is quite common in patients receiving primary care, medical professionals often fail to recognize and adequately treat the disease. These medications alleviate the usually associated depression symptoms as well. Selective Serotonin Reuptake Inhibitor (SSRI) are well-tolerated and effective for both anxious and depressive symptoms, making the primary option for treating agoraphobia with PD in the short, medium, and long term. SSRIs which are less likely to cause withdrawal symptoms after abrupt discontinuation should be used for long-term prophylaxis. Tricyclic Antidepressant (TCA) can be a second-line therapy for PD if SSRIs don't work, although venlafaxine hasn't been researched long-term. High-potency medications are advantageous choices for short-term therapy since ithas been shown to have a quick start of anti-anxiety action, having favorable benefits. Cognitive-Behavioral Therapy (CBT), which is the non-pharmacological approach that has gotten the most research, can be employed with a variety of patients depending on how easily it is accessible.

Keywords: Panic Disorder (PD); Diagnosis; Agoraphobia; Symptoms; Treatment Options.

RESUMEN

La agorafobia con trastorno de pánico (TP) es una condición de fobia-ansiedad que hace que quienes la padecen eviten situaciones o lugares en los que podrían sentirse avergonzados o ser incapaces de salir o conseguir ayuda en caso de un TP. La agorafobia se ha asociado al síndrome de EP recurrente durante los últimos 50 años y, en muchos casos, se considera que representa la progresión o complicación normal del EP. Aunque la agorafobia con EP es bastante común en pacientes que reciben atención primaria, los profesionales médicos a menudo no reconocen ni tratan adecuadamente la enfermedad. Estos medicamentos alivian también los síntomas de depresión que suelen ir asociados. Los inhibidores selectivos de la recaptación de serotonina (ISRS) se toleran bien y son eficaces tanto para los síntomas ansiosos como para los depresivos, por lo que son la principal opción

para tratar la agorafobia con EP a corto, medio y largo plazo. Para la profilaxis a largo plazo deben utilizarse ISRS que tengan menos probabilidades de causar síntomas de abstinencia tras una interrupción brusca. Los antidepresivos tricíclicos (ATC) pueden ser una terapia de segunda línea para la EP si los ISRS no funcionan, aunque la venlafaxina no se ha investigado a largo plazo. Los medicamentos de alta potencia son opciones ventajosas para la terapia a corto plazo, ya que se ha demostrado que tienen un inicio rápido de acción ansiolítica, con beneficios favorables. La terapia cognitivo-conductual (TCC), que es el enfoque no farmacológico que más se ha investigado, puede emplearse con una variedad de pacientes en función de la facilidad de acceso.

Palabras clave: Trastorno de Pánico (TP); Diagnóstico; Agorafobia; Síntomas; Opciones de Tratamiento.

INTRODUCTION

The classification of significant anxiety, depressive disorder, and obsessive-compulsive disorder (OCD) as distinct diagnostic entities provides an initial basis for comprehending the commonalities between these conditions. Many people with depression also experience symptoms of anxiety and many people with OCD also experience symptoms of anxiety and depression. Additionally, other factors can complicate the picture, such as the fact that symptoms of anxiety, depression, and OCD can sometimes be caused by underlying medical conditions or medication side effects.[1] Early epidemiological surveys of mental health used simple self-report measures of psychiatric symptoms to gather information about the frequency of psychological fitness conditions in the population. These surveys often relied on questionnaires or interviews that asked people about their experiences of symptoms such as anxiety, depression, and substance use. While these measures can be useful for identifying potential cases of mental illness. Additionally, relying solely on self-report measures can sometimes lead to over diagnosis or under diagnosis of mental health conditions, as these measures cannot always be able to distinguish between normal emotional experiences and symptoms that meet analytic criteria for mental health confusion.[2] PD is mental health conditions characterized by recurrent, unpredicted PD which is an unexpected period of concentrated panic or anxiety that reach a hit the highest point can the transcript. A significant functional impairment, a worse quality of life, and more frequent use of medical services are all related to PD. People with PD can avoid certain situations or activities that fear could trigger a PD, which can limit their ability to engage in daily activities or participate in social situations. Untimely opinion and effective behavior can help to advance outcomes and reduce the negative impact of the disorder on a person's life.[3] Pathological anxiety, such as social phobia, has indeed been present in humans throughout history. However, the present is some evidence to recommend that there can be an enhancement in anxiety-related disorders in the 21st century. One possible reason for this increase is the impact of modern lifestyle and technological advancements on our daily lives. The widespread use of Smart phones and social media can contribute to increased levels of anxiety and social phobia, as inhabitants can feel pressure to constantly stay connected and present a convincing image of themselves online. In addition, the fast-paced nature of modern society and the increased demand for productivity and achievement can contribute to higher levels of stress and anxiety. This can be especially true in urban areas where there is often a high level of competition and pressure to succeed.[4] Anxiety disorder is highly prevalent and carries a significant burden globally. Anxiety confusion is the majority of ordinary cerebral strength disorders universal, with a predictable 274 million people affected. Anxieties disorders are capable of including a significant impact on a personnel's excellence of existence, including their social, occupational, and personal functioning. Specified the far above-the-ground prevalence and burden of anxiety disorder, it is significant for healthcare professionals to contain a comprehensive sequence to guide decisions about how best to supervise these conditions.[5] Anxiety and depression can exacerbate seizure frequency, increase the risk of suicide, and reduce adherence to treatment regimens. Moreover, People with Epilepsy (PWE) with anxiety and depression often report higher levels of stigma and social isolation, which can further contribute to their psychological distress and impact their overall well-being. As a result, the present is an upward appreciation of the high occurrence and associated burden of anxiety and depression in PWE, and the need for effective screening and treatment of these comorbidities.[6] These interventions typically involve the use of digital platforms, such as websites or mobile apps, to deliver therapeutic content and support to individuals who cannot have access to or prefer not to engage in traditional face-to-face therapy. Studies have shown that can be as efficient as established face to face therapy for situations such as despair, concern, and post-traumatic stress disorder (PTSD).[7] Contemporary psychodynamic models of anxiety disorders focus on the role of unconscious conflicts, defenses, and early life experiences in the expansion and preservation of concern symptoms.

These models propose that anxiety symptoms are a result of internal conflicts between unconscious wishes or impulses and opposing fears or prohibitions, which are managed through the use of various defense mechanisms.

[8] While psychodynamic models of anxiety disorders and their associated treatments cannot be as well-known or widely used as other approaches such as CBT, there is increasing empirical support for the efficiency of these treatments in reducing symptoms and improving functioning in individuals with anxiety disorders.[9] Apprehension and depressive disorder are both common and debilitating mental health conditions that have a significant impact on individuals and society as a whole. The anxiety and depressive disorders affect roughly 35 % of the inhabitants throughout their existence. These conditions are characterized by continual feelings of sadness or anxiety, loss of interest or pleasure in activities, and other physical and emotional symptoms that can interfere with daily functioning. Moreover, concern and depressive disorders are leading contributors to the global burden of disease, secretarial for 10 % of existence lived with disability. These conditions can significantly impact an individual's quality of life and functioning, leading to problems such as social isolation, decreased productivity, and difficulty in personal relationships. [10,11] Mixed-methods research looked at the viability, user occurrence, and property of a recently created transdiagnostic guide online intrusion for concern disorder. The utilization of interventions, user experience, impact, and adjustment requests, together with motivation and expectations. Semi-structured interviews were used to evaluate qualitative data, and qualitative content analysis was used to examine the results. The quantitative results included the level of concern and depressed symptoms. The benefits of online therapy, the severity of the symptoms, and receptivity to online treatment were the most common justifications for involvement.[12] The existence of comorbidity can have a variety of effects on the course of the illness. Comorbidity in people with a Seasonal Affective Disorder (SAD) is associated with earlier management on the lookout for behavior, an increase in symptom intensity, resistance to treatment, and poorer functioning. A discussion of the main mental comorbidities that can be present during SAD as well as the diagnostic and treatment difficulties that can result from comorbidities.[13] An investigator-initiated clinical research with a parallel-group, assessor-blinded, and superiority-designed structure used.[14] Mesmerizing compulsive, delicate stress and post-traumatic stress disorders were eliminated from expanded on how anxiety disorders are defined. The distinctions between the categories of anxiety disorders for children and adults were diminished. Growing data also shows that agoraphobia is different from PD.[15] It is necessary to display for, estimate, diagnose, and perhaps begin behavior for anxiety disorders in primary care settings since this is where the majority of persons with anxiety disorders seek therapy for the first time. Anxiety disorders can cause considerable psychological, social, and vocational damage itis not treated appropriately. The flight-or-fight reaction is a kind of fear response that can be triggered by elevated anxiety levels.[16] Anxiety disorder etiology, developmental, and prognostic variables are explored. There is a short examination of certain neurobiological elements and psychosocial elements that can support the development of anxiety disorders. For evaluating a client who can have an anxiety problem, assessment techniques, and psychometric inventories are given. The effectiveness of many therapies is studied, including but not limited to CBT. A viewpoint on anxiety disorders is presented, and it is also discussed if it could be time for the Church to change its stance on psychology and psychotherapy. Prevention tactics and implications for future research are also included.[17] In the research, suggestions for the psychopharmacological management of various illnesses are provided. Various suggestions are supported by thorough treatment guidelines, meta-analyses, and systematic reviews of the available randomized controlled trials. Pharmacotherapy, psychotherapy, or a combination of the two is all effective treatments for anxiety disorders. Serotonin-norepinephrine reuptake inhibitors (SNRIs) and SSRIs are first-line medications. Due to their propensity for addiction, benzodiazepines are not advised for daily usage. Tricyclic antidepressants, buspirone, moclobemide, and other medications are additional therapy choices in addition to the calcium modulator pregabalin. Psychological therapies and drug treatment can be combined.[18] To calculate the incidence of anxiety disorders in pregnant and postpartum women and to find the factors that influence estimates' variability. Without regard to time or language, an electronic search of PsycINFO and PubMed was carried out from the beginning to July 2016 and was augmented by papers that were cited in the sources that were found. Pregnancy, postpartum, prevalence, and particular anxiety disorders were combined into a Boolean search query.[19.20] It explains environmental brief assessment and its benefits, which include the capacity to gather ecologically reliable data on mental diseases in real-time, for specific patients.[21] Incidence rates for all anxiety disorders should be considered while creating preventative strategies and long-term treatment plans. Over the 20 years, anxiety disorder incidence rates considerably rose. The prevalence of anxiety disorders varied greatly, from 0,01 to 23,70. The incidence rates of the various anxiety disorders varied greatly, with Unilateral Aural Deafness (UAD) having the highest prevalence. These findings emphasize the need of treating anxiety problems by medical experts.[22] The goal of the present research is to provide a general overview of important characteristics of anxiety symptoms and anxiety disorders (AD) in adult PWE. AD is identified during intricate intervals and happens apart from seizures. Predictive anxiety of epileptic seizures Anxiety about Seizures (AAS), seizure phobia, epileptic social phobia, and epileptic PD are four distinct AD in PWE that can be objectified. The second sections outline the bidirectional path physiological connection between anxiety and epilepsy. Some individuals have seizures as a result of worry, and understanding the connection between anxiety and seizures requires an understanding of stress and arousal.[23] The distinctions

between anxiety disorders are sometimes ill-defined, and depending on the terminology used, instances can differ greatly. Simple phobia, agoraphobia, and Generalized Anxiety Disorder (GAD) are more prevalent in Vernon, but SP (Social Phobia), PD (Panic Disorder) and OCD (Obsessive-Compulsive Disorder) are not gender-specific. The incidence of anxiety disorders is greatest in those between the ages of 25 and 44 and lowest in people over 65. Separated, divorced, and bereaved people are more likely to have anxiety disorders.[24] This research gives an outline of the role that psycho-physiological research can play in attempts to better understand anxiety disorders.[25] Starting with the behavioral domain, it is shown that protective behaviors, which are key to anxiety disorders, are dynamically arranged according to the closeness of a particular danger are shown in figure 1.



Figure 1. Analysis of Agoraphobia and Panic Disorder

DEVELOPMENT

PDS AND AGORAPHOBIA AS PSYCHOPATHOLOGIES

A PD is an abrupt, unexpected, and short-lived anxiety episode marked by the dread of passing out, fainting, leaving crazy, or otherwise abandoning control of one activity, as glowing as a wide variety of somatic and psycho sensorial sensations that stack moreover pass away in a matter of minutes. Many people can have restricted, “minor” episodes marked by one or two symptoms and less acute perceptual anxiety rather than the complete spectrum of normal symptoms that accompany a PD. Disorders that repeat or are followed by strong anxiety for at least four weeks qualify as having a PD. Following the commencement of spontaneous panic episodes, patients often have concomitant continuous fear about disorders returning and live in a constant state of nervous anticipation. This phenomenon differs from the disorders themselves in that it lasts for a longer period (hours), intensifies gradually, and patients can typically tell it apart from a PD. Although a PD can strike suddenly under any circumstance, a certain kind of circumstance appears to be more likely to cause one than others. Patients are taught to stay away from circumstances where are less likely to get assistance, such as being alone or leaving familiar surroundings. Being alone at home, leaving, being in cramped, dark, unlocked, otherwise burning spaces, going into a store, shopping center elevator, balcony, public road, or train outside of a certain radius from one residence or municipality are some common situations that a clinician investigating a patient with agoraphobia should looked. The agoraphobic syndrome is caused by a fear of having a PD; sufferers are terrified of places where cannot be able to escape or receive treatment if have a PD. Figure 2 shows Agoraphobia develops when avoidance behavior becomes widespread and severe enough to seriously impair day-to-day functioning, employment, and social interaction. Some patients could find utterly unable to leave the house or can only be able to do so with the help of a reliable companion. Rarely, patients can experience terror during intercourse, consumption, pleasing a shower, washing their hair, or anticipatory worry, all of which are not characteristic of an agoraphobic condition. Patients can also have an increase in the frequency of PDs. Usually; patients have more or less conscious associations with these circumstances for the onset of their first PD.

https://doi.org/10.56294/hl2025610



Figure 2. Progression of Panic attack and disorder

AGORAPHOBIA DIAGNOSIS

The attendance of nervousness in circumstances or else locations where people fear being humiliated, being stuck, or not being able to receive aid in the event of a PD. Whenever possible, feared circumstances are avoided, or it cannot be avoided, are handled with considerable discomfort or the worry of going through PDs, or call for the company of a reliable friend. Such the formal scientific conference can be used to analyze agoraphobia in agreement criteria. The investigative classification makes a distinction between situations in which agoraphobia takes place with recurrent panic episodes and situations in which an agoraphobic condition exists exclusive of such a narration. If no current evidence of PDs can be identified, a history of PD should be thoroughly addressed. These observations, however, can have been skewed. An underestimation of the prevalence of PD can have resulted from the adoption of indicative hierarchies that disallow the judgment of PD when depression is present. Additionally, the inclusion of non-proven researchers in some of the research can have made it more difficult to detect a chronic phobic condition like agoraphobia than a syndrome with a phase course, such as PD. This viewpoint contends that agoraphobia is not a subgroup of PD but rather a complicated disease. The majority of clinical research concurs with the idea that PDs are the first psychopathological sign of PD, whereas defensive concern, irrational worries, and irrational avoidance follow. These could be some of the explanations for why epidemiological research indicates a high incidence of agoraphobia without panic episodes yet clinical practice seldom ever diagnoses agoraphobia without a history of PDs. Another explanation for the discrepancy is that “pure” agoraphobia, defined as the absence of a history of PDs, is as common in the population as epidemiological research indicate, but that the vast majority of sufferers do not seek medical attention because have become accustomed to the lifestyle restrictions of agoraphobic avoidance and do not experience acute anxious phenomena, making invisible to routine clinical practice and unresearched in clinical studies.

HIGH DEMAND FOR MEDICAL SERVICES

Instead of a primary complaint involving worry or terror, many people who later get a PD diagnosis initially seek medical assistance for somatic problems. The capacity to experience spontaneous or situational anxiety, as well as what their primary source of dread or worry is, varies greatly. Some patients only express a broad sense that something is amiss with their bodies or their lives, reacting to somatic symptoms or nervous hyper arousal with an explanatory model that there is something physically wrong with rather than a mental health issue. Compared to mania and severe depression, which are both 200 times more likely to be present in patients who present with many unexplained symptoms, PD is 200 times more likely to be present in such patients. Studies have also shown that people with PD use medical services more often than average, as can be predicted. According to one research, men and women who had six or more medical visits in the previous six

months were five and eight times more likely, figure 3 depicts the diagnosis of PD than people who had fewer than six visits, while the chances of having depression or substance use disorders were significantly lower. Additionally, according to epidemiological studies, patients with PD are more likely to make six or more visits to a general practitioner during a year than other psychiatric and non-psychiatric groups, and also more likely to be identified as high healthcare users.



Figure 3. Necessity for Healthcare

Clinical features of agoraphobia

Agoraphobia can sometimes start right away following the initial panic episode, but it usually develops gradually over many weeks or months of recurrent PDs or persistent anticipatory worry. Some individuals have variable anticipatory anxiety and progressively develop agoraphobia over the years, while others start with regular panic episodes or chronic worry and become housebound in a matter of weeks. Although the frequency of the episodes often reduces as avoidance behavior becomes organized, agoraphobic individuals can continue to have PDs for years. After the first stages of the condition, panic episodes can stop occurring in some people, while phobic avoidance can develop into an agoraphobic lifestyle. When the coping mechanism is rendered ineffective, such as in widowhood or during a move, the real intensity of the phobic-anxious condition can only become apparent. Over time, feared circumstances can remain constant or can evolve and build, often during a cyclical recurrence of manic episodes. The condition can progressively develop as more circumstances become dreaded and the scope of individual liberty is reduced. Table 1 and figure 4 describe the patient in this case going from an individual incapable to constrain away from his or her town or visit a restaurant, to just being able to walk and avoiding busy places, to being housebound alone. Untreated PD often has a recurrent, chronic course that lasts for years or even decades, albeit in one research, one-third of the patients had remitted after an eleven-year follow-up. The course of PD varies greatly from patient to patient; some suffer from PDs without avoiding for years, while others immediately acquire minor hypochondria's is, social anxiety, agoraphobia, etc. Premenstrual phase PDs in women are more frequent and more severe, although it tends to become better throughout pregnancy. Depressed episodes affect one-third of patients who are treated in a mental health environment, and the development of depressed symptoms is a frequent occurrence.

Table 1. People with values experiencing agoraphobia

Features	Frequency of agoraphobia
Nausea and vomiting	1
Not finding toilet	2
Imbalance and falling	1
Bathroom phobia	10
Being home alone	31
Leaving home alone	33
Elevator	3
The bus, subway, car, and plane	1
Crossing the bridge	0
Crowd and standing	16



Figure 4. Individuals experiences with agoraphobia

Treatment of pd and agoraphobia

The preparation of the patient for therapy, use of straightforward pharmacological algorithms, incorporation of an informal cognitive-behavioral approach, and use of straightforward rating scales to track results can all enhance treatment outcomes in PD. Treatment cannot be necessary for these situations until phobic avoidance significantly impairs social functioning. Charting the spectrum of phobic circumstances from the most tolerable to the most dreaded can help examine patients' avoidance behaviors to the fullest degree possible. Table 2 and figure 5 Discussing the negative effects of the condition on daily life, such as avoiding routine tasks, work, studies, and relationships, as well as the successful nature of adjusting to prevention, could help patients stay motivated to complete their therapy. Physicians should advise patients to refrain from actions that can raise their anxiety levels, such as drinking alcohol or coffee, getting little sleep, or exercising. According to several research, exercising can help prevent PDs and reduce anxiety before events. Patients who have limited autonomy due to phobic avoidance be supposed to be confident to participate in several kinds of standard indoor implementation. People who can refrain from exercising out of concern that would have a disorder should be made aware that regular exercise can lessen the frequency of PDs, release stress, and enhance sleep.

Table 2. Comparison of prevalence

	Prevalence				
	Phobias	**Worry**	**PTSD**	**Panic**	**Fear of falling**
Childhood	80	60	12	10	0
Adolescence	69	52	20	12	0
Adulthood	42	33	25	14	0
Old age	25	49	20	2	40

https://doi.org/10.56294/hl2025610



Figure 5. Changes in Age-related anxiety disorder

Summary of the treatment

A substantial amount of investigation supports the idea that CBT and pharmaceutical management with medications for depression can be successful therapies for PD. Meta-analyses claim that CBT alone is more effective in treating PD symptoms than either medication alone or combined therapy, although these studies' conclusions are debatable due to major methodological errors. According to figure 6 a more recent meta-analysis, pharmacotherapy and CBT are both more successful than excuse and no-treatment control, and medicinal effects therapy can be just as beneficial as CBT. Additionally, there were no discernible changes between the combined strategy and CBT or pharmaceutical treatment used alone. A different recent meta-analysis found that combination therapy was superior to depression medications and psychotherapy unaided in acute-phase treatment. In the long run, combination treatment was just as successful as psychotherapy and better than medication alone. Short-term pharmacological therapy with benzodiazepines has been proven to be as effective as antidepressants, while there are worries regarding the long-term adverse effects of these medications.



Figure 6. Consequences of panic disorder

https://doi.org/10.56294/hl2025610

CONCLUSIONS

Patients undergoing edge dialysis are a unique group of people. Many individuals experience some amount of despair after learning has end-stage renal disease. Although PD is relatively prevalent in both psychiatrists and primary care settings, many patients do not get a quick diagnosis and proper pharmaceutical or cognitive-behavioral management. In the last 20 years, there have been notable advancements in the treatment of PD. SSRIs, TCAs, high-potency benzodiazepines, CBT, and other effective therapy approaches are now accessible for the temporary supervision of this illness. CBT is the most thoroughly researched non-pharmacological method and, subject to availability can be used with a wide range of patients. Pharmaceutical therapy with antidepressants, depending on its availability, CBT can be used with a wide range of patients and is the non-pharmacological technique that has received the most research. The most common form of therapy in psychiatric and general practitioner settings is the pharmaceutical cure with medications, primarily SSRIs, under circumstances of regular medical observation it is an efficient and secure method for treating PD symptoms in the majority of treatments. Resuming pharmaceutical therapy typically results in a less severe re-emergence of PD symptoms that can be readily managed. A key element in sustaining permanent remission after treatment discontinuation seems to be the degree of clinical remission attained after therapy. Future research could explore the efficacy of these alternative therapies and compare to traditional treatments.

REFERENCES

1. Goodwin GM. The overlap between anxiety, depression, and obsessive-compulsive disorder. Dialogues in clinical neuroscience. 2015 Sep 30;17(3):249-60. https://doi.org/10.31887/DCNS.2015.17.3/ggoodwin

2. Stein DJ, Scott KM, De Jonge P, Kessler RC. Epidemiology of anxiety disorders: from surveys to nosology and back. Dialogues in clinical neuroscience. 2017 Jun 30;19(2):127-36. https://doi.org/10.31887/DCNS.2017.19.2/dstein

3. Stech EP, Grierson AB, Chen AZ, Sharrock MJ, Mahoney AE, Newby JM. Intensive one-week internet-delivered cognitive behavioral therapy for panic disorder and agoraphobia: A pilot study. Internet interventions. 2020 Apr 1;20:100315. https://doi.org/10.1016/j.invent.2020.100315

4. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues in clinical neuroscience. 2015 Sep 30;17(3):327-35. https://doi.org/10.31887/DCNS.2015.17.3/bbandelow

5. Scott AJ, Bisby MA, Heriseanu AI, Hathway T, Karin E, Gandy M, Dudeney J, Staples LG, Titov N, Dear BF. Understanding the untreated course of anxiety disorders in treatment-seeking samples: A systematic review and meta-analysis. Journal of anxiety disorders. 2022 Jun 1;89:102590. https://doi.org/10.1016/j.janxdis.2022.102590

6. Apolinário-Hagen J, Drüge M, Fritsche L. Cognitive behavioral therapy, mindfulness-based cognitive therapy and acceptance commitment therapy for anxiety disorders: integrating traditional with digital treatment approaches. Anxiety disorders: Rethinking and understanding recent discoveries. 2020:291-329. https://doi.org/10.1007/978-981-32-9705-0_17

7. Rakitzi S. Agoraphobia. InClinical Psychology and Cognitive Behavioral Psychotherapy: Recovery in Mental Health 2023 Apr 1 (pp. 65-71). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-031-27837-2_8

8. Cohen JN, Kaplan SC. Understanding and treating anxiety disorders: a psychodynamic approach. Clinical Handbook of Anxiety Disorders: From Theory to Practice. 2020:315-32. https://doi.org/10.1007/978-3-030-30687-8_17

9. Davies MR, Buckman JE, Adey BN, Armour C, Bradley JR, Curzons SC, Davies HL, Davis KA, Goldsmith KA, Hirsch CR, Hotopf M. Comparison of symptom-based versus self-reported diagnostic measures of anxiety and depression disorders in the GLAD and COPING cohorts. Journal of Anxiety Disorders. 2022 Jan 1; 85:102491. https://doi.org/10.1016/j.janxdis.2021.102491

10. Scott AJ, Sharpe L, Thayer Z, Miller LA, Nikpour A, Parratt K, Wong T, Gandy M. How frequently is anxiety and depression identified and treated in hospital and community samples of adults with epilepsy?. Epilepsy & Behavior. 2021 Feb 1;115:107703. https://doi.org/10.1016/j.yebeh.2020.107703

11. Patel TA, Schubert FT, Hom MA, Cougle JR. Correlates of treatment seeking in individuals with social

anxiety disorder: Findings from a nationally representative sample. Journal of Anxiety Disorders. 2022 Oct 1; 91:102616. https://doi.org/10.1016/j.janxdis.2022.102616

12. Weisel KK, Zarski AC, Berger T, Krieger T, Moser CT, Schaub MP, Görlich D, Berking M, Ebert DD. User experience and effects of an individually tailored transdiagnostic internet-based and mobile-supported intervention for anxiety disorders: mixed-methods study. Journal of Medical Internet Research. 2020 Sep 16;22(9): e16450. https://doi.org/10.2196/16450

13. Koyuncu A, İnce E, Ertekin E, Tükel R. Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges. Drugs in context. 2019 Apr 2; 8:212573. https://doi.org/10.7573/dic.212573

14. Arnfred B, Bang P, Hjorthøj C, Christensen CW, Moeller KS, Hvenegaard M, Agerskov L, Gausboel UK, Soe D, Wiborg P, Smith CI. Group cognitive behavioural therapy with virtual reality exposure versus group cognitive behavioural therapy with in vivo exposure for social anxiety disorder and agoraphobia: a protocol for a randomised clinical trial. BMJ open. 2022 Feb 1;12(2):e051147.doi:10.1136/bmjopen-2021-051147

15. Wiebe A, Kannen K, Selaskowski B, Mehren A, Thöne AK, Pramme L, Blumenthal N, Li M, Asché L, Jonas S, Bey K. Virtual reality in the diagnostic and therapy for mental disorders: A systematic review. Clinical Psychology Review. 2022 Dec 1; 98:102213. https://doi.org/10.1016/j.cpr.2022.102213

16. Park SC, Kim YK. Anxiety disorders in the DSM-5: changes, controversies, and future directions. Anxiety Disorders: Rethinking and Understanding Recent Discoveries. 2020:187-96. https://doi.org/10.1007/978-981-32-9705-0_12

17. Simon N, Hollander E, Rothbaum BO, Stein DJ, editors. The american psychiatric association publishing textbook of anxiety, trauma, and ocd-related disorders. American Psychiatric Pub; 2020 Apr 2.

18. Bandelow B. Current and novel psychopharmacological drugs for anxiety disorders. Anxiety disorders: Rethinking and understanding recent discoveries. 2020:347-65. https://doi.org/10.1007/978-981-32-9705-0_19

19. Fawcett EJ, Fairbrother N, Cox ML, White IR, Fawcett JM. The prevalence of anxiety disorders during pregnancy and the postpartum period: a multivariate Bayesian meta-analysis. The Journal of clinical psychiatry. 2019 Jul 23;80(4):1181.

20. Walter HJ, Bukstein OG, Abright AR, Keable H, Ramtekkar U, Ripperger-Suhler J, Rockhill C. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. Journal of the American Academy of Child & Adolescent Psychiatry. 2020 Oct 1;59(10):1107-24. https://doi.org/10.1016/j.jaac.2020.05.005

21. Lorenzo LS. Beyond the 'normal'worries: Detection and treatment of perinatal anxiety and anxiety disorders. BJPsych Advances. 2023 May;29(3):187-97. https://doi.org/10.1192/bja.2022.922.

22. Ebenfeld L, Stegemann SK, Lehr D, Ebert DD, Funk B, Riper H, Berking M. A mobile application for panic disorder and agoraphobia: Insights from a multi-methods feasibility study. Internet Interventions. 2020 Mar 1; 19:100296. https://doi.org/10.1016/j.invent.2019.100296

23. Good BJ, Kleinman AM. Culture and anxiety: Cross-cultural evidence for the patterning of anxiety disorders. InAnxiety and the anxiety disorders 2019 Jan 22 (pp. 297-324). Routledge.

24. Russell PD, Judkins JL, Blessing A, Moore B, Morissette SB. Incidences of anxiety disorders among active-duty service members between 1999 and 2018. Journal of Anxiety Disorders. 2022 Oct 1; 91:102608. https://doi.org/10.1016/j.janxdis.2022.102608

25. Luong HK, Drummond SP, Norton PJ. Elements of the therapeutic relationship in CBT for anxiety disorders: A systematic review. Journal of anxiety disorders. 2020 Dec 1;76:102322. https://doi.org/10.1016/j.janxdis.2020.102322

FUNDING

None

CONFLICT OF INTEREST

None

AUTHOR CONTRIBUTIONS

Conceptualization: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Data curation: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Formal analysis: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Research: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Methodology: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Project management: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Resources: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Software: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Supervision: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Validation: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Visualization: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Drafting – original draft: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

Drafting – review and editing: Devraj Singh Chouhan, Saumya Das, Prateek Garg, Nagireddy Mounika, Swamyvel Sethuraman, Nittin Sharma.

https://doi.org/10.56294/hl2025610